发明授权
US5925624A 2,6-Di (substitutedamino) purine ribonucleoside analogues and
administration to treat respiratory inflammation
失效
2,6-Di（取代氨基）嘌呤核糖核苷类似物并给予治疗呼吸道炎症
- 专利标题： 2,6-Di (substitutedamino) purine ribonucleoside analogues and administration to treat respiratory inflammation
- 专利标题（中）： 2,6-Di（取代氨基）嘌呤核糖核苷类似物并给予治疗呼吸道炎症
-
申请号： US446727申请日： 1995-09-18
-
公开(公告)号： US5925624A公开(公告)日： 1999-07-20
- 发明人: Michael Gregson , Barry Edward Ayres, deceased , George Blanch Ewan , Frank Ellis , John Knight
- 申请人： Michael Gregson , Barry Edward Ayres, deceased , George Blanch Ewan , Frank Ellis , John Knight
- 申请人地址： GBX London
- 专利权人： Glaxo Group Limited
- 当前专利权人： Glaxo Group Limited
- 当前专利权人地址： GBX London
- 优先权： GBX9301000 19930120
- 主分类号： A61K31/70
- IPC分类号： A61K31/70 ; A61K31/7042 ; A61K31/7052 ; A61K31/7076 ; A61P1/00 ; A61P9/00 ; A61P11/00 ; A61P29/00 ; A61P35/04 ; A61P37/00 ; A61P37/06 ; A61P37/08 ; C07H19/16 ; C07H19/167
摘要：
The present invention relates to 2,6-diaminopurine-.beta.-D-ribofuranuronamide derivatives of the following formula (I). These compounds and their salts and solvates are useful as anti-inflammatory agents, particularly in the treatment of patients with inflammatory conditions who are susceptible to leukocyte-induced tissue damage. ##STR1##
公开/授权文献
- US5055040A Tooth shade selection using a new comparator 公开/授权日：1991-10-08